股票名称 回购数 回购额 年累计回购数量(股) 年累计回购数量/总股本 蒙牛乳业(02319) 70.00 万 1014.14 万 1921.60 万 0.491% 云工场(N23027) 187.40 万 753.34 万 2451.70 万 5.330% 联易融科技-W(09959) 245.00 万 743.93 万 6543.90 万 3.063% 固生堂(02273) 23.20 万 683.52 万 467.81 万 1.974% 安东油田服务 (03337) 442.40 万 494.16 万 3369.20 万 1.140% 伟仕佳杰(00856) 50.00 万 453.30 万 663.80 万 0.462% 北森 控股(09669) 40.06 万 323.92 万 143.26 万 0.204% 中旭未来(09890) 22.82 万 313.05 万 598.58 万 1.120% 首 佳科技(00103) 280.00 万 221.20 万 5745.20 万 2.445% 美丽田园医疗健康(02373) 7.00 万 220.95 万 30.05 万 0.127% 康臣药业(01 ...

智通财经APP讯，加科思-B(01167)发布公告，于2025年10月20日该公司斥资99.7万港元回购12.69万股， 回购价格为每股7.8-7.9港元。 ...

加科思-B(01167)发布公告，于2025年10月20日该公司斥资99.7万港元回购12.69万股，回购价格为每股 7.8-7.9港元。 ...

格隆汇10月20日丨加科思-B(01167.HK)公告，10月20日耗资99.7万港元回购12.7万股。 ...

公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年10月20日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括 ...

Core Viewpoint - The company, 加科思-B, has seen a significant stock price increase following the announcement of a strategic equity transfer agreement with 海松资本, which will enhance its focus on key oncology pipeline products [1] Group 1: Stock Performance - 加科思-B's stock rose over 7% during trading, with a current increase of 6.12%, reaching HKD 7.8, and a trading volume of HKD 23.94 million [1] Group 2: Strategic Agreement - The company signed an equity transfer agreement with 海松资本 and an industry partner, where 海松资本 will pay RMB 125 million as an initial payment and RMB 75 million as a milestone payment to acquire 80% of 加科瑞康 [1] - Following the completion of this transaction, 加科思's ownership in 加科瑞康 will decrease to 10% [1] Group 3: Strategic Focus - The transaction aligns with the company's strategy to focus on critical oncology pipeline products targeting various key cellular pathways, including KRAS, MYC, P53, and tumor immunity [1] - The proceeds from the equity transfer, after taxes and fees, will be allocated to the development, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [1]

Core Viewpoint - The stock of 加科思-B (01167) has seen a significant increase, rising over 7% during trading, attributed to a strategic equity transfer agreement with 海松资本 and an industry partner, aimed at optimizing capital allocation and focusing on key oncology pipeline products [1] Group 1: Stock Performance - 加科思-B's stock price increased by 6.12%, reaching 7.8 HKD, with a trading volume of 23.94 million HKD [1] Group 2: Strategic Agreement - 加科思 has signed an equity transfer agreement where 海松资本 will pay a total of 2 billion RMB (1.25 billion RMB upfront and 750 million RMB milestone payment) to acquire 80% of 加科瑞康 [1] - Following the completion of this transaction, 加科思's ownership in 加科瑞康 will decrease to 10% [1] Group 3: Strategic Focus - The transaction aligns with the company's strategy to focus on critical oncology pipeline products, including KRAS, MYC, P53, and tumor immunology [1] - The proceeds from the equity transfer will be used for the research, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [1]

Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].

股票名称 回购数 回购额 年累计回购数量(股) 年累计回购数量/总股本 小米集团-W(01810) 1070.00 万 4.94 亿 2729.54 万 0.110% 四环医药(00460) 1500.00 万 2175.75 万 5959.60 万 0.647% 蒙牛乳业(02319) 120.00 万 1696.90 万 1851.60 万 0.473% 瑞声科技(02018) 30.00 万 1159.88 万 30.00 万 0.026% 速腾聚创 (02498) 29.00 万 991.75 万 29.00 万 0.061% 中通快递-W(02057) 44.50 万 840.97 万 506.72 万 0.630% VITASOY INT'L(00345) 102.00 万 819.55 万 566.60 万 0.540% 云工场(N23027) 202.00 万 814.36 万 2264.30 万 4.922% 联易融科技-W(09959) 252.00 万 744.46 万 6298.90 万 2.948% 碧桂园服务(06098) 100.00 万 618.60 万 1125.50 万 0 ...

Summary of Key Points Core Viewpoint - 加科思-B (01167.HK) announced a share buyback of 135,000 shares at a cost of HKD 990,000 on October 17 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 990,000, reflecting the company's financial strategy [1] - The number of shares repurchased was 135,000, which may influence the stock's liquidity and market perception [1]